Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05688280 · ClinicalTrials.gov registry record · Phase 1
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
A Phase 1 study of Colon Cancer and Soft Tissue Sarcoma, sponsored by Immunophotonics.
- Active
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 16
- Study locations
NCT05688280 is a Phase 1 study of Colon Cancer and Soft Tissue Sarcoma that is active but no longer recruiting, run by Immunophotonics. The registered enrollment target is 42 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 4 states.
The verdict
NCT05688280, a Phase 1 study of Colon Cancer and Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Immunophotonics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
Conditions Studied
Interventions
- DRUG 1.0% IP-001 for Injection
Study Locations (16)
Other
- Institut Bergonie - Bordeaux
- Hospitalier Pitie-Salpetriere - Paris
- Hôpital Foch - Suresnes
- Institut Gustave Roussy - Villejuif
- Johann Wolfgang Goethe-Univresitat Frankfurt/Main - Frankfurt
- SLK-Kliniken Heilbronn GmbH - Heilbronn
- Munchen Klinik Bogenhausen - Munich
- IOSI Ospedale San Giovanni Bellinzona - Bellinzona
- Inselspital Universitatsspital, Bern - Bern
- Kantonsspital Graubunden - Chur
- Kantonsspital St. Gallen - Sankt Gallen
- University College London Hospitals - London
- Churchill Hospital - Oxford
Florida
- Miami Cardiac & Vascular Institute - Coral Gables
Kentucky
- University of Louisville Physicians, PSC - Louisville
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2025-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05688280
The ClinicalTrials.gov registry entry for NCT05688280 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Immunophotonics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which 1.0% IP-001 for Injection is the first listed.
NCT05688280 reports 16 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT05688280 about?
NCT05688280 is a clinical study titled "Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS". The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
What is the current status of trial NCT05688280?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-11-29. Estimated completion is 2025-02.
What conditions does trial NCT05688280 study?
This clinical trial studies the following conditions: Colon Cancer, Soft Tissue Sarcoma, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer.
What interventions are being tested in trial NCT05688280?
The interventions under investigation include: 1.0% IP-001 for Injection (DRUG).
Who is sponsoring clinical trial NCT05688280?
This trial is sponsored by Immunophotonics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05688280 being conducted?
This trial has 16 study locations across Florida, Kentucky, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
RECRUITING · Phase 1
-
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.